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Summary The autologous and allogeneic immunological humoral response of breast cancer patients to
breast tumours was investigated by ELISA assay of both the serum and the supernatants of transformed
lymphocytes from the patients and controls. No specificity or increased titre relative to the controls was
observed in serum antibody. However, when the response was dissected by the use of clones of transformed
lymphocytes from the patients, considerable specificity could be demonstrated in certain clones while other
clones showed a generalised specificity which contributed to the masking of the specific response in the serum.
Some of these clones may have clinical potential as diagnostic and prognostic tools.
The concept of the existence of a significant
immune response to autologous tumour tissue in
most patients with malignant disease has
widespread acceptance among immunologists and
clinicians (Herberman, 1983). Such a response may
be effected through either humoral or cellular
mechanisms or by natural killer cells. Clearly the
immortalisation of the B lymphocyte response
through human hybridoma production could lead
to the production of a valuable clinical reagent for
diagnosis. However, this presupposes that the B
lymphocyte response to the tumour is specific and
does not cross react with other tissues.
Rodent hybridomas directed against solid
tumours have been employed in both diagnosis and
therapy but none of the rodent monoclonal
antibodies available are totally specific to tumour
antigens and tumour associated antigens are
generally employed as targets. However, rodent
hybridomas are generated by xenogeneic
immunisation which may favour the production of
antibodies to major antigens on the tumour tissue
which are not specific to its malignant phenotype.
Clearly the human response to autologous tumour
may reflect a different, and much more relevant
spectrum of specificities since, for example,
antibodies to histocompatibility antigens are less
likely to dominate.
Breast cancers may be classified according to
stage, histological grade, or content of one of
several biochemical markers (Hawkins et al., 1980).
Of these latter, oestrogen receptor status gives,
perhaps, the most independent information about
the biology of the tumour (Leake, 1984). Presence
of oestrogen receptor is associated with improved
survival (Knight et al., 1977; Bishop et al., 1979) as
well as being an indicator of potential for response
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to endocrine therapy of advanced disease (Hawkins
et al., 1980). Inclusion of an index of functional
receptor, such as translocation of oestrogen
receptor to the nucleus (Leake et al., 1981) or
induction of progesterone receptor (Osborne et al.,
1980) can improve the discriminatory value of
receptor status. As receptor, in teleological terms, is
associated with only the final stages of
differentiation of the breast cell line, it is reasonable
to suppose that receptor positive cells might have
cell surface markers not found on receptor negative
cells.
Therefore, assuming that patients with breast
cancer have specific serum antibodies directed
against their own tumours, it may be possible to
differentiate receptor positive and negative tumours
serologically.
The data presented in this paper show that little
or no specificity in response to autologous tumours
can be demonstrated by serum titre but that the
response can be dissected by examining the
antibody production of cloned transformed B
lymphocytes from the patients so that specific
antibody production may be selected out from the
non-specific generalised tissue responses.
Materials and methods
Patients
All patients attended the Breast Cancer clinics at
either the Division of Surgery, Victoria Infirmary,
or the Department of Surgery, Western Infirmary,
Glasgow. Blood (20ml) was taken from each
patient prior to surgery. The excised portion of
tumour was divided into three, one sample for
pathological examirittion, one for oestrogen
receptor analysis, and one to be processed for assay
as described below. Both patients were late
menopausal and both had Grade I adenocarcinoma
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of the breast. All material was transferred to the
laboratory on ice and used fresh unless otherwise
stated.
ELISA assay
Fresh tumours were dissected by scalpel in PBS and
then gently pressed through a wire mesh of grid size
2mm with the plunger section of a hypodermic
syringe. The cells were then centrifuged at 2000g
for 10min and examined by phase contrast
microscopy for intactness. Cells (104) were plated
into individual wells of ELISA plates (Dynatech)
which had been pretreated for 1 h with poly-L-
lysine (Sigma) at 10ugml-1 and centrifuged at
600g for 5min. The cells were then fixed with 0.1%
glutaraldehyde for 3min and the plates were stored
at 4°C in I00mM glycine, 0.1% sodium azide, 1%
normal goat serum and 0.5% bovine serum
albumin (BSA) in PBS until required for assay.
Tumour cells were never frozen as, even when this
was performed in liquid nitrogen under cell culture
storage techniques, the majority of the tumour cells
were not intact on thawing.
In the ELISA assay, the plates were first blocked
with I00MI of BSA at 50mgml-1 in PBS
containing 1% heat inactivated normal goat serum
for 2h at room temperature and then reacted with
100pl of serum or clonal supernatant at the
required dilution. Dilution was with PBS containing
0.5% BSA and 0.1% Tween 20. Controls for serum
were antigen with diluent and for clonal
supernatants tissue culture medium. Incubation
with specific antibody was overnight at 4°C. The
supernatant was then flicked off and the wells were
washed three times with PBS containing 0.05%
Tween 20 before the addition of rabbit anti human
IgG (H+L) (Miles 1/1000) conjugated to
horseradish peroxidase. After 3G inin at room
temperature, the wells were washed as before and
then incubated with the substrate mixture (0-
phenylene diamine at 0.4mgml-1 in citrate
phosphate buffer containing 0.01% fresh H202)
(Campbell, 1984). The reaction was stopped with
50 Sl 4N H2SO4 and the absorbance at 492nm was
measured in a Titretrek Multiskan spectrophoto-
meter. Tumour backgrounds for any particular
patient varied between 0.5 and 0.9A492 units
reflecting binding of second antibody to the
tumour. The relative absorbance of any patient on
any particular tumour, however, always showed
identical patterns. Wells which gave a reading 20%
above background or greater were taken as
positive.
Transformation ofcells with Epstein Barr virus
The B lymphocytes from 20ml of fresh blood were
purified and transformed exactly as described by
Campbell (1984) with Epstein Barr virus obtained
from B95-8 cells. Cells were plated out at 104
cells/well and assayed after 2-3 weeks when growth
was evident. This does not represent 1 cell/well
cloning which is not possible at this stage and the
statistical possibility of more than one specificity
within the same well must be considered. However,
with most patients, the larger number of negative
clones indicates that this possibility is remote.
Positives of selected specificity were expanded and
backfused with the HAT sensitive ouabain resistant
KR4 cell line (Kozbor et al., 1982) in order to
stabilise the clones and increase secretion. Positives
from this fusion were then cloned at 1 cell/well and
retested for specificity profile.
Results
Early in the study, it became apparent the serum
antibody response of the large number of breast
cancer patients tested (over 20) showed a
measurable titre against autologous and allogeneic
tumour but that no definite pattern of specificity to
autologous tumour or. tumours of similar receptor
status was evident. The data are best shown when
normal controls are also tested. Figure 1 shows the
typical serum response of a tumour patient to
autologous tumour cells in comparison to five
normal controls, two male and three female. The
controls show an equally strong response to that of
the patients indicating that the antibody binding
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Figure 1 Autologous serum response to breast cancer
measured by ELISA assay. Receptor positive patient
(dotted line) assayed on her own tumour and controls.
Triangles represent male controls and other symbols
female controls. Similar data were obtained from
receptor negative patients with respect to controls.
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observed probably reflects specific antibodies
directed towards general cellular antigens. The
alternative explanation, that the controls also carry
specific antibodies to the breast tumours, must also
be considered. There was no obvious distinction
between receptor positive and receptor negative
tumours.
The serum response to cellular antigens is clearly
composed of many different specificities and
affinities. In addition, it is possible that specific
serum antibody may not be detected because it is
complexed to antigen and not available for assay. It
may therefore be anticipated that the purified
transformed lymphocytes from the patients will
yield more detailed information about the humoral
response. The antibody production of the
lymphocytes from the tumour patients was
therefore assessed after Epstein Barr virus
transformation. Specificity was analysed on four
different tumours. The first was autologous tumour,
the second tumour of opposite receptor status, the
third a different epithelial tumour, in this case
endometrial, and the fourth a tumour of diverse
origin, in this case, uveal melanoma which is a
sarcoma. In this way, the response of the cloned
lymphocytes could be assessed for specificity to
breast tumour of a particular receptor status,
specificity to all breast tumours, specificity to
epithelial tumours and general specificity to all four
tumours tested. The profile obtained from the
tumour of a patient is shown in Figure 2 and the
data from patients and controls are summarised in
Table I. It is apparent that a wide range of
specificities was encompassed by the serum
response. Since a relatively small number of clones
have been tested from each patient, the diversity of
serum response may well be even greater than is
shown.
The response of the controls in Figure 1
indicated clearly that normal subjects carry
antibodies which react with breast tumours and
consequently the specificity profiles of both normal
male and normal female were also assessed and
are shown in Table I. Again, a wide range of speci-
ficity is apparent. The observation that clones
reactive only with receptor positive tumours
(A+B-E-M-) are dominant in receptor positive
patients whereas clones reactive with receptor
negative tumours (A-B+E-M-) may be found
in all patients and controls illustrates one specificity
of interest.
Discussion
The data clearly indicate that the measureable
specific serum response of any patient to her own
tumour is small when compared to normal controls.
Several interpretations of this observation are
possible. Firstly, the B lymphocyte response to
autologous tumour may indeed be very limited and
the major immune response may be mediated by T
lymphocytes. However, it is also possible that
specific serum antibody is not available for ELISA
Patient B (R-)
Assayed on patient B
50 -ve (B-)
Assayed on patient A
10 +ve (B+)
Assayed on patient A
50 -ve (AWE 6 +ve (A+B+) Assayed on 4 -ve (A-B+)
uveal melanoma
3 -ve (A+B+M-) 3 +ve (A+B+M+) 4 -ve (A-B+M-)
Assayed on primary endometrial tumour
2 -ve 1 +ve 3 +ve 3 +ve 1-
(A+B+E-M-) (A+B+E+M-) (A+B+E+M+) (A-B+E+M--) (A-B+E
-ve
-M-)
Figure 2 ELISA assay of Epstein Barr virus transformed B lymphocytes from a receptor negative breast
cancer patient. Clones were first assayed on autologous tumour and scored as B + or B-. They were then
assayed on a receptor positive tumour (A) and scored for antigens expressed on both (A+B+), receptor
negative only (A-B+). Selected clones of each class were then assayed on a primary endometrial tumour
and primary unveal melanoma and scored in the same way. The clones which are underlined were selected for
expansion and backfusion.10 A.M. CAMPBELL et al.
Table I Percentage of clones with each type of reaction profile from patients and normal
controls
Receptor positive Receptor negative Normal controls
tumourpatient tumour patient (male andfemale)
A+B-E-M- 44 0 2
A+B+E-M- 22 20 33
A-B+E-M- 22 10 25
A+B+E+M- 0 10 17
A-B-E+M+ 0 0 2
A-B+E+M- 0 30 2
A-B-E-M+ 0 0 2
A+B+E+M+ 12 30 15
Data derived from flow charts as in Figure 2. A, receptor positive breast tumour. B,
receptor negative breast tumour. E, endometrial tumour. M, eye melanoma.
assay as it is involved in immune complex
formation with tumour cells or shed antigen. If this
is the case, then the clonal supernatants of the B
lymphocytes may be expected to reveal antibodies
not detectable in the serum. Both patients did in
fact display antibody producing capacity which
appeared to be directed to the autologous tumour
only while the bulk of the clones cross reacted with
other tumour tissue. Thus, from this limited survey,
it would appear that certain clones reflect a
reasonably specific response which is masked by
non-specific response in the serum. It should
however be noted that anti-breast tumour reactivity
is also detectable in the normal controls.
The heterogenous nature of breast cancers is well
recognised (Carter, 1984). Indeed, the importance
of assessing the cellularity of any breast tumour in
relation to quantitative analysis of markers has
been extensively discussed in relation to oestrogen
receptors (see Leake, 1984 for review). It is,
therefore, not reasonable to assign the interactions
described here purely to adenocarcinoma cells.
However, experiments with ZR75-1 cells (an
oestrogen receptor positive breast cancer cell line)
have indicated that three out of four
A+B-E-M- clones interact with this line
whereas no other clones do. This would indicate
that the interactions are principally with epithelial
cells. The cellular oestrogen receptor is, of course,
an intracellular and probably intranuclear protein
(Welshons et al., 1984). However, the existence of
specific plasma membrane associated oestrogen
binding proteins has been discussed by several
authors (Peterson & Ceriani, 1985).
The response of normal individuals to the
tumours can be attributed either to a genuine self
response to common tissue antigens released by
normal cell destruction and physiologically
regulated by the idiotypic network, or to a non-
specific response where antibodies elicited by some
other environmental antigen cross react with the
self antigen when tested on a highly sensitive assay.
Thus, for example, clones of B lymphocytes
secreting antibodies reactive with antigens such as
DNA and thyroglobulin have been isolated from
normal individuals (Winger et al., 1983). The
significance of these anti-tumour antibodies in the
defence of the patient against her own tumour may
well be limited since even specific antibody may
result from a secondary response to shed tumour
antigens rather than a primary defence mechanism.
However, the dissection of the specificity profiles in
this manner does make the task of selection of
clones potentially suitable for diagnosis possible at
an early stage.
In human hybridoma production, positive clones
are generally selected shortly after transformation
for backfusion with a HAT sensitive, ouabain
resistant cell line which amplifies antibody secretion
and stabilises antibody production. Fusion and
cloning procedures are both costly and time
consuming and it is clearly preferable to select,
from among the early positives, those clones which
secrete antibody likely to be of clinical application
after stabilisation. The procedure described here
enables some of this early selection to be accom-
plished. The A+B-E-M- and A-B+E-M-
clones may in fact have too great a specificity as
general reagents but in view of the considerable
heterogeneity observed in breast cancer and in
normal breast epithelial cells (Edwards, 1985), it
is likely that a panel of clones will be required for
clinical work to cover the range of patients. These
clones have been backfused and cloned at 1 cell/well
and retain their original specificity which can be
extended to other tumours of the same receptor
status. The A+B+E-M- clones may appear to
be more general breast tumour reagents but it is
possible that their specificity range may be too
broad for clinical application. However, they haveAUTOLOGOUS BREAST CANCER RESPONSE 11
also been backfused and cloned. Human mono-
clonal antibodies generally require several cloning
cycles before they are finally, if ever, stabilised
and this procedure is now under way with all the
described clones remaining positive four months
after the original transformation and three months
after backfusion. However, it will be several
months before their stability can be finally assessed.
This work was funded by the Cancer Research Campaign.
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